EE200100645A - Amüloidogeense haiguse preventsioon ja ravi - Google Patents

Amüloidogeense haiguse preventsioon ja ravi

Info

Publication number: EE200100645A
Authority: EE; Estonia
Prior art keywords: amyloid; prevention; treatment; fibril; disclosed
Prior art date: 1999-06-01

Application number

EEP200100645A

Other languages

English (en)

Inventor

B. Schenk Dale

Original Assignee

Neuralab Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-01

Filing date

2000-06-01

Publication date

2003-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22475417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200100645(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-01 Application filed by Neuralab Limited filed Critical Neuralab Limited

2003-02-17 Publication of EE200100645A publication Critical patent/EE200100645A/et

2011-12-15 Publication of EE05492B1 publication Critical patent/EE05492B1/et

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Pathology (AREA)
Biophysics (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Mycology (AREA)
Obesity (AREA)

EEP200100645A 1999-06-01 2000-06-01 Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral EE05492B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13701099P	1999-06-01	1999-06-01
PCT/US2000/015239 WO2000072876A2 (en)	1999-06-01	2000-06-01	Prevention and treatment of amyloidogenic disease

Publications (2)

Publication Number	Publication Date
EE200100645A true EE200100645A (et)	2003-02-17
EE05492B1 EE05492B1 (et)	2011-12-15

Family

ID=22475417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100645A EE05492B1 (et)	1999-06-01	2000-06-01	Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral

Country Status (31)

Country	Link
US (8)	US7977316B2 (et)
EP (2)	EP1185296B1 (et)
KR (3)	KR100930559B1 (et)
CN (2)	CN101091795A (et)
AT (1)	ATE495755T1 (et)
AU (1)	AU5316300A (et)
BG (1)	BG65756B1 (et)
BR (1)	BR0011103A (et)
CA (1)	CA2375104C (et)
CY (1)	CY1111639T1 (et)
CZ (1)	CZ302971B6 (et)
DE (1)	DE60045550D1 (et)
EA (1)	EA200101250A1 (et)
EE (1)	EE05492B1 (et)
ES (2)	ES2445799T3 (et)
HK (1)	HK1045117B (et)
HR (1)	HRP20010893A2 (et)
HU (1)	HU229986B1 (et)
IL (3)	IL146563A0 (et)
IS (1)	IS2925B (et)
MX (1)	MXPA01012293A (et)
NO (1)	NO20015758L (et)
NZ (2)	NZ587223A (et)
PL (1)	PL202217B1 (et)
PT (1)	PT1185296E (et)
SG (2)	SG147275A1 (et)
SK (1)	SK288207B6 (et)
TR (1)	TR200103469T2 (et)
UA (1)	UA81216C2 (et)
WO (1)	WO2000072876A2 (et)
ZA (1)	ZA200109662B (et)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9706957D0 (en)	1997-04-05	1997-05-21	Smithkline Beecham Plc	Formulation
US8173127B2 (en) *	1997-04-09	2012-05-08	Intellect Neurosciences, Inc.	Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
GB9820525D0 (en)	1998-09-21	1998-11-11	Allergy Therapeutics Ltd	Formulation
WO2000048630A1 (en)	1999-02-17	2000-08-24	Csl Limited	Immunogenic complexes and methods relating thereto
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
ES2275570T3 (es)	1999-12-08	2007-06-16	Intellect Neurosciences, Inc.	Peptidos amiloides beta quimericos.
GB0000891D0 (en)	2000-01-14	2000-03-08	Allergy Therapeutics Ltd	Formulation
KR100767146B1 (ko)	2000-02-24	2007-10-15	워싱톤 유니버시티	Ａβ 펩티드를 격리시키는 인간화 항체
CA2404237C (en)	2000-04-05	2010-01-26	University Of Tennessee Research Corporation	Methods of investigating, diagnosing, and treating amyloidosis
AU2007200047B2 (en) *	2000-07-07	2009-11-26	Bioarctic Neuroscience Ab	Prevention and treatment of Alzheimer's disease
EP1309341A2 (en)	2000-07-07	2003-05-14	Lars Lannfelt	Prevention and treatment of alzheimer's disease
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
EP2165714B1 (en)	2001-04-30	2013-10-23	Eli Lilly And Company	Humanized antibodies recognizing the beta-amyloid peptide
AU2002257162A1 (en)	2001-04-30	2002-11-11	Eli Lilly And Company	Humanized antibodies
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
PT1944040E (pt)	2001-08-17	2012-10-31	Univ Washington	Método de avaliação para a doença de alzheimer
AU2002366355A1 (en) *	2001-12-17	2003-06-30	New York State Office Of Mental Health	SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2003055514A1 (en) *	2001-12-21	2003-07-10	Antigenics Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
CA2493119A1 (en) *	2002-07-17	2004-01-22	Mindset Biopharmaceuticals Usa Inc.	Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
US20070213512A1 (en) *	2002-10-01	2007-09-13	Krafft Grant A	Amyloid beta peptide analogs and assemblies thereof
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US8697082B2 (en)	2002-11-01	2014-04-15	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en)	2003-10-31	2015-05-19	Prothena Biosciences Limited	Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en)	2003-10-31	2008-01-17	Elan Pharmaceuticals, Inc.	Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE602004027348D1 (de)	2003-02-10	2010-07-08	Applied Molecular Evolution	Abeta-bindende moleküle
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
ES2246178B1 (es) *	2003-05-08	2007-03-01	Universidad De Zaragoza.	Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
ES2640669T3 (es)	2003-05-19	2017-11-03	Prothena Biosciences Limited	Fragmentos truncados de alfa-sinucleína en enfermedad con cuerpos de lewy
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
US7807171B2 (en)	2003-07-25	2010-10-05	Ac Immune Sa	Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US7674599B2 (en)	2003-11-08	2010-03-09	Elan Pharmaceuticals, Inc.	Methods of using antibodies to detect alpha-synuclein in fluid samples
EP1717250A4 (en) *	2004-02-20	2008-10-01	Immuno Biological Lab Co Ltd	MONOCLONAL ANTIBODY AND ITS USE
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
KR101068289B1 (ko)	2004-07-30	2011-09-28	리나트 뉴로사이언스 코퍼레이션	아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
EA013752B1 (ru)	2004-08-09	2010-06-30	Элан Фармасьютикалз, Инк.	Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
CA2590337C (en)	2004-12-15	2017-07-11	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en)	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
CN101506236B (zh)	2005-11-30	2012-12-12	雅培制药有限公司	抗淀粉样β蛋白的单克隆抗体及其用途
DK1954718T3 (en)	2005-11-30	2014-12-15	Abbvie Inc	Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
CN105924521A (zh) *	2005-11-30	2016-09-07	Abbvie 公司	抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
DE602007011415D1 (de)	2006-03-23	2011-02-03	Bioartic Neuroscience Ab	Verbesserte protofibrilselektive antikörper und deren verwendung
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
WO2009017467A1 (en)	2007-07-27	2009-02-05	Elan Pharma International Limited	Treatment of amyloidogenic diseases
AU2007301981A1 (en) *	2006-09-25	2008-04-03	Universiteit Maastricht	Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr)	2007-01-05	2014-02-28	University Of Zürich	Anti beta-amiloid antitijela i njihova upotreba
AU2008203703C1 (en)	2007-01-05	2014-04-03	University Of Zurich	Method of providing disease-specific binding molecules and targets
SI3067066T1 (sl)	2007-02-23	2019-08-30	Prothena Biosciences Limited	Preventiva in zdravljenje sinukleinopatske in amiloidogene bolezni
US8147833B2 (en)	2007-02-23	2012-04-03	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
DK3067066T3 (da)	2007-02-23	2019-05-20	Prothena Biosciences Ltd	Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
US20100311767A1 (en)	2007-02-27	2010-12-09	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
WO2008133208A1 (ja) *	2007-04-20	2008-11-06	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	ペプチド免疫応答増強方法
CN101861164B (zh) *	2007-08-09	2014-12-10	西尔万医药有限公司	朊病毒蛋白相关疾病的治疗
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP3470079A1 (en)	2008-04-29	2019-04-17	BioArctic AB	Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
HRP20150831T1 (hr)	2008-12-19	2015-10-09	Biogen International Neuroscience Gmbh	Humana anti-alfa- sinuklein auto-protutijela
LT2539366T (lt)	2010-02-26	2018-04-25	Bioarctic Ab	Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduose
KR20110111594A (ko) *	2010-04-05	2011-10-12	서울대학교산학협력단	알파-시뉴클레인 유래 곱슬 아밀로이드 섬유의 제조방법, 이를 이용한 하이드로젤의 제조 방법 및 그 이용 방법
MX360403B (es)	2010-04-15	2018-10-31	Abbvie Inc	Proteinas de union a amiloide beta.
CN103037891A (zh) *	2010-06-03	2013-04-10	雷蒙特亚特特拉维夫大学有限公司	治疗糖尿病的方法和能够治疗糖尿病的组合物
CN102311499A (zh) *	2010-07-09	2012-01-11	博生吉医药科技(苏州)有限公司	一种癌症治疗用人源化单克隆抗体及其制备及应用
EP2603233A1 (en)	2010-08-12	2013-06-19	AC Immune S.A.	Vaccine engineering
JP6147665B2 (ja)	2010-08-14	2017-06-14	アッヴィ・インコーポレイテッド	アミロイドベータ結合タンパク質
TW201223561A (en)	2010-10-26	2012-06-16	Ac Immune Sa	Preparation of an antigenic construct
US9512185B2 (en) *	2011-06-01	2016-12-06	Xiamen University	Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof
BR112013033258B1 (pt)	2011-06-23	2022-09-20	University Of Zurich	Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos
DK2579042T3 (da)	2011-10-04	2014-07-21	Affiris Ag	Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
AU2015286707B2 (en)	2014-07-10	2020-05-21	Bioarctic Neuroscience Ab	Improved A beta protofibril binding antibodies
CN105616405B (zh) *	2014-11-05	2021-05-07	中国人民解放军第三军医大学第三附属医院	依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用
MA41115A (fr)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
US9879080B2 (en)	2015-01-28	2018-01-30	Prothena Biosciences Limited	Anti-transthyretin antibodies
US10633433B2 (en)	2015-01-28	2020-04-28	Prothena Biosciences Limited	Anti-transthyretin antibodies
US10464999B2 (en)	2015-01-28	2019-11-05	Prothena Biosciences Limited	Anti-transthyretin antibodies
EP3070096A1 (en) *	2015-03-19	2016-09-21	Ludwig-Maximilians-Universität München	A peptide or collection of peptides derived from amyloid precursor protein
JP7065516B2 (ja)	2015-11-09	2022-05-12	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータのｎ末端エピトープおよびそれに対する立体配座選択的抗体
CA3004494A1 (en)	2015-11-09	2017-05-18	The University Of British Columiba	Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374383A4 (en)	2015-11-09	2019-05-15	The University Of British Columbia	AMYLOID BETA EPITOPES AND ANTIBODIES
JP7204192B2 (ja)	2015-11-24	2023-01-16	マサチューセッツインスティテュートオブテクノロジー	認知症の予防、軽減、及び／または治療のためのシステムならびに方法
CN116333108A (zh)	2016-07-18	2023-06-27	英属哥伦比亚大学	淀粉样蛋白β的抗体
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3067597C (en)	2017-06-29	2023-03-21	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies for treatment of amyloid deposition diseases
US12286469B2 (en)	2017-07-18	2025-04-29	The University Of British Columbia	Humanized antibodies binding to amyloid-beta (A-beta)
WO2019023247A1 (en)	2017-07-25	2019-01-31	Immutics, Inc.	TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
US11382974B2 (en) *	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
RS64289B1 (sr)	2017-08-22	2023-07-31	Biogen Ma Inc	Farmaceutske kompozicije koje sadrže anti-amiloid beta antitela
CU24731B1 (es)	2017-10-06	2025-01-15	Prothena Biosciences Ltd	Anticuerpos anti-transtiretina
PE20210042A1 (es)	2017-10-06	2021-01-08	Prothena Biosciences Ltd	Metodos para detectar transtiretina
CA3078704A1 (en)	2017-10-10	2019-04-18	Massachusetts Institute Of Technology	Systems and methods for preventing, mitigating, and/or treating dementia
MX2020005433A (es)	2017-11-29	2020-08-27	Prothena Biosciences Ltd	Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
GB201720975D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Anti-alpha synuclein antibodies
GB201720970D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Antibodies
US12018069B2 (en)	2018-06-28	2024-06-25	The Trustees Of Columbia University In The City Of New York	Methods and compositions for imaging amyloid deposits
CN115359999A (zh)	2018-11-02	2022-11-18	台达电子企业管理（上海）有限公司	变压器模块及功率模块
US20210400932A1 (en) *	2018-11-09	2021-12-30	Neurimmune Ag	Patient-derived amyloid xenograft non-human animal model
KR102135130B1 (ko) *	2019-02-15	2020-07-17	충북대학교 산학협력단	트랜스타이레틴 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
JP2023528797A (ja)	2020-05-26	2023-07-06	トゥルーバインディング，インコーポレイテッド	ガレクチン－３を遮断することにより炎症性疾患を処置する方法
CN116528888A (zh) *	2020-10-30	2023-08-01	拉什大学医学中心	用于治疗阿尔兹海默症的鼻内免疫疗法
CN115475247B (zh) *	2021-06-16	2024-02-20	厦门大学	β2-微球蛋白或其抑制剂的制药用途
WO2023099788A1 (en) *	2021-12-03	2023-06-08	Neurimmune Ag	Novel potency assay for antibody-based drugs and useful means therefor
TWI824398B (zh) *	2022-01-27	2023-12-01	慈濟學校財團法人慈濟大學	一種肌動蛋白重組調節物之抑制劑用於製備治療睡眠剝奪引起之記憶退化之藥物之用途
WO2024121156A1 (en) *	2022-12-05	2024-06-13	Neurimmune Ag	Cyclic compounds and their use in assays for detecting antibodies

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US14692A (en) *		1856-04-15		Improved diaphragm fluid-meter
US573547A (en) *		1896-12-22		smith
US73655A (en) *		1868-01-21		Improvement in safety-pockets
CH652145A5 (de)	1982-01-22	1985-10-31	Sandoz Ag	Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4443427A (en)	1982-06-21	1984-04-17	Sidney Farber Cancer Institute, Inc.	Monoclonal antibody
US4634666A (en)	1984-01-06	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Human-murine hybridoma fusion partner
US5208036A (en)	1985-01-07	1993-05-04	Syntex (U.S.A.) Inc.	N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en)	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
DE3687751T2 (de)	1985-09-19	1993-05-27	Toray Industries	Kolonne zum entfernen von beta-2-mikroglobulin.
US4641473A (en) *	1985-12-23	1987-02-10	Trezza Ronald F	Clip construction for wall arrangement
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5231170A (en)	1986-08-27	1993-07-27	Paul Averback	Antibodies to dense microspheres
GB8625435D0 (en) *	1986-10-23	1986-11-26	Erba Farmitalia	Human apolipoprotein ai
US5220013A (en)	1986-11-17	1993-06-15	Scios Nova Inc.	DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en)	1986-11-17	1993-02-16	Scios Nova Inc.	Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5290762A (en)	1986-12-24	1994-03-01	John Lezdey	Treatment of inflammation
DE3702789A1 (de)	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
EP0279582A3 (en)	1987-02-17	1989-10-18	Pharming B.V.	Dna sequences to target proteins to the mammary gland for efficient secretion
GB8720115D0 (en) *	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
US4883666A (en)	1987-04-29	1989-11-28	Massachusetts Institute Of Technology	Controlled drug delivery system for treatment of neural disorders
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
US5583112A (en)	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5849298A (en)	1987-06-24	1998-12-15	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of bovine myelin
US5645820A (en)	1987-06-24	1997-07-08	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en)	1987-06-24	1996-11-05	Autoimmune, Inc.	Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5641474A (en)	1987-06-24	1997-06-24	Autoimmune, Inc.	Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en)	1987-06-24	1996-11-05	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5869054A (en)	1987-06-24	1999-02-09	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of autoantigens
DE3856566T2 (de)	1987-06-24	2004-06-24	Brigham And Women's Hospital, Boston	Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
US5231000A (en)	1987-10-08	1993-07-27	The Mclean Hospital	Antibodies to A4 amyloid peptide
CA1339014C (en)	1987-10-08	1997-03-25	Ronald E. Majocha	Antibodies to a4 amyloid peptide
EP0382781B1 (en)	1987-10-23	1993-09-29	Genetics Institute, Inc.	Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
US5266561A (en) *	1988-01-11	1993-11-30	Amylin Pharmaceuticals, Inc.	Treatment of type 2 diabetes mellitus
AU3056289A (en)	1988-01-13	1989-08-11	Mclean Hospital Corporation, The	Genetic constructs containing the alzheimer brain amyloid gene
US5785973A (en) *	1988-02-01	1998-07-28	Praxis Biologics, Inc.	Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2006700A1 (en)	1989-01-17	1990-07-17	Antonello Pessi	Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1990012870A1 (en)	1989-04-14	1990-11-01	Research Foundation For Mental Hygiene, Inc.	Monoclonal antibody to amyloid peptide
AU5439790A (en)	1989-04-14	1990-11-16	Research Foundation For Mental Hygiene, Inc.	Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
CA2017507C (en)	1989-05-25	1996-11-12	Gary Van Nest	Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5262303A (en)	1989-10-13	1993-11-16	Trustees Of Boston University	Ligand/anti-ligand assays for adherent proteins
IT1237764B (it)	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
JP2625253B2 (ja)	1989-12-20	1997-07-02	オートイミューンインク	吸入投与形態をとる自己免疫疾患および／または予防用薬剤
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
ATE157257T1 (de)	1990-03-02	1997-09-15	Autoimmune Inc	Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
US5279833A (en)	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
EP0451700A1 (en)	1990-04-10	1991-10-16	Miles Inc.	Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
EP0527823A1 (en)	1990-04-24	1993-02-24	The Regents Of The University Of California	Purification, detection and methods of use of protease nexin-2
US5753624A (en)	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
EP0526511B1 (en)	1990-04-27	1997-05-28	MCMICHAEL, John	Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
ES2109945T3 (es)	1990-06-01	1998-02-01	Chiron Corp	Composiciones y procedimientos para identificar moleculas biologicamente activas.
US5593970A (en)	1990-06-11	1997-01-14	Biochem Pharma Inc.	Heterocyclic anthracycline analogs
AU646877B2 (en)	1990-06-15	1994-03-10	Scios Nova Inc.	Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
ATE185601T1 (de)	1990-07-10	1999-10-15	Cambridge Antibody Tech	Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5780587A (en)	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
NZ239643A (en) *	1990-09-17	1996-05-28	North American Vaccine Inc	Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2092823A1 (en)	1990-09-28	1992-03-29	Barry D. Greenberg	Transgenic animals with alzheimer's amyloid precursor gene
WO1992006708A1 (en)	1990-10-15	1992-04-30	Brigham And Women's Hospital	Treatment of autoimmune diseases by oral administration of autoantigens
ATE447016T1 (de)	1991-01-21	2009-11-15	Elan Pharm Inc	Prüfung und modell für alzheimers-krankheit
US5192753A (en)	1991-04-23	1993-03-09	Mcgeer Patrick L	Anti-rheumatoid arthritic drugs in the treatment of dementia
US5858657A (en)	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
DE69230142T2 (de)	1991-05-15	2000-03-09	Cambridge Antibody Technology Ltd.	Verfahren zur herstellung von spezifischen bindungspaargliedern
LU91067I2 (fr)	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5672805A (en)	1991-07-18	1997-09-30	The Regents Of The University Of California	Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US5434050A (en)	1991-08-13	1995-07-18	Regents Of The University Of Minnesota	Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5283185A (en)	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
ATE148889T1 (de)	1991-09-18	1997-02-15	Affymax Tech Nv	Verfahren zur synthese der verschiedenen sammlungen von oligomeren
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
JPH07506720A (ja)	1992-01-07	1995-07-27	アテナ　ニューロサイエンシーズ，　インコーポレイテッド	アルツハイマー病のトランスジェニック動物モデル
US5679348A (en)	1992-02-03	1997-10-21	Cedars-Sinai Medical Center	Immunotherapy for recurrent HSV infections
EP1958646A1 (en)	1992-02-11	2008-08-20	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Dual carrier immunogenic construct
US5314813A (en)	1992-02-19	1994-05-24	Scripps Research Institute	Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
CA2117492C (en)	1992-02-28	2009-04-07	Howard L. Weiner	Bystander suppression of autoimmune diseases
DK0640131T3 (da) *	1992-03-17	1999-11-01	Novartis Ag	Gensplejsere antistoffer
EP0561087B1 (en)	1992-03-20	1999-08-04	N.V. Innogenetics S.A.	Mutated form of the beta-amyloid precursor protein gene
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5604102A (en)	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) *	1992-04-15	1995-08-15	Athena Neurosciences, Inc.	Methods for monitoring cellular processing of β-amyloid precursor protein
GB9209118D0 (en)	1992-04-28	1992-06-10	Sb 120 Amsterdam Bv	Vaccine compositions
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en)	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994001772A1 (en)	1992-07-13	1994-01-20	The Children's Medical Center Corporation	SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
WO1994003615A1 (en)	1992-07-31	1994-02-17	Medeva Holdings B.V.	Expression of recombinant fusion proteins in attenuated bacteria
US5958883A (en)	1992-09-23	1999-09-28	Board Of Regents Of The University Of Washington Office Of Technology	Animal models of human amyloidoses
IL107166A (en)	1992-10-01	2000-10-31	Univ Columbia	Complex combinatorial chemical libraries encoded with tags
DK1298436T3 (da) *	1992-10-26	2010-10-25	Elan Pharm Inc	Fremgangsmåde til identificering af inhibitorforbindelser for frisætning af beta-amyloidpeptid (BAP)
US5605811A (en)	1992-10-26	1997-02-25	Athena Neurosciences, Inc.	Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
WO1994012629A1 (en)	1992-12-02	1994-06-09	Baylor College Of Medicine	Episomal vectors for gene therapy
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0683234B2 (en)	1993-01-25	2007-06-06	Takeda Chemical Industries, Ltd.	Antibody against beta-amyloid or their derivative and use thereof
US5955317A (en)	1993-01-25	1999-09-21	Takeda Chemical Industries, Ltd.	Antibodies to β-amyloids or their derivatives and use thereof
CA2115900A1 (en)	1993-02-22	1994-08-23	Gerald W. Becker	Pharmaceutical screens and antibodies
US5776468A (en)	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5643562A (en) *	1993-03-29	1997-07-01	Queen's University Of Kingston	Method for treating amyloidosis
ATE221387T1 (de) *	1993-04-27	2002-08-15	United Biomedical Inc	Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe
WO1994028412A1 (en)	1993-05-28	1994-12-08	The Miriam Hospital	Composition and method for in vivo imaging of amyloid deposits
ATE215124T1 (de)	1993-07-30	2002-04-15	Medeva Holdings Bv	Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
US5724322A (en) *	1993-08-10	1998-03-03	Sony Corporation	Apparatus for recording and/or reproducing a recording medium with editing function
US5728385A (en) *	1993-08-12	1998-03-17	Classen Immunotherapies, Inc.	Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
AU705889B2 (en)	1993-08-26	1999-06-03	Regents Of The University Of California, The	Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
EP0735893B1 (en)	1993-09-14	2008-11-26	Pharmexa Inc.	Pan dr-binding peptides for enhancement of the immune response
US5446650A (en) *	1993-10-12	1995-08-29	Tektronix, Inc.	Logic signal extraction
AU683703B2 (en)	1993-10-20	1997-11-20	Duke University	Method of binding material to the beta-amyloid peptide
EP0726906A4 (en)	1993-11-02	1998-10-07	Affymax Tech Nv	THE SYNTHESIS AND EXAMINATION OF MOLECULAR DIVERSITY
US5744368A (en)	1993-11-04	1998-04-28	Research Foundation Of State University Of New York	Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US5434170A (en)	1993-12-23	1995-07-18	Andrulis Pharmaceuticals Corp.	Method for treating neurocognitive disorders
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5914349A (en)	1994-01-10	1999-06-22	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
AU1909695A (en)	1994-01-27	1995-08-15	Regents Of The University Of Minnesota	Transgenic non-human mammals with progressive neurologic disease
US5877399A (en)	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0802797A1 (en)	1994-02-03	1997-10-29	The Picower Institute For Medical Research	Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
AU691296B2 (en)	1994-05-06	1998-05-14	Pharmacopeia Drug Discovery, Inc.	Combinatorial dihydrobenzopyran library
DE69521700T2 (de) *	1994-05-25	2001-10-25	John Mcmichael	Mittel und methoden zur behandlung von plaque-krankheiten
US5505947A (en)	1994-05-27	1996-04-09	The University Of North Carolina At Chapel Hill	Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en)	1994-06-14	1997-04-22	Protein Design Labs, Inc.	Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5663046A (en)	1994-06-22	1997-09-02	Pharmacopeia, Inc.	Synthesis of combinatorial libraries
US6417178B1 (en)	1994-07-19	2002-07-09	University Of Pittsburgh	Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6114133A (en)	1994-11-14	2000-09-05	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en)	1994-12-16	1997-11-18	Ramot University Authority For Applied Research And Development Ltd.	Prevention of protein aggregation
US5786180A (en)	1995-02-14	1998-07-28	Bayer Corporation	Monoclonal antibody 369.2B specific for β A4 peptide
DE69621607T2 (de)	1995-03-14	2003-01-02	Praecis Pharmaceuticals Inc., Waltham	VERBINDUNGEN MIT AGGREGATIONS-MODULIERENDEN WIRKUNG AUF DAS AMYLOiD PROTEIN
US7153510B1 (en)	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
DE19518147B4 (de) *	1995-05-17	2013-09-05	Günther Nath	UV-stabiler Flüssigkeitslichtleiter
AU6113896A (en)	1995-06-05	1996-12-24	Brigham And Women's Hospital	Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
US5948763A (en)	1995-06-07	1999-09-07	New York University	Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
PT750907E (pt)	1995-06-30	2002-08-30	American Cyanamid Co	Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao
US5671500A (en) *	1995-08-07	1997-09-30	Balk; Brett	Overhead door spring shield system
WO1997006809A1 (en)	1995-08-21	1997-02-27	Cytrx Corporation	Compositions and methods for growth promotion
JP3713074B2 (ja)	1995-08-30	2005-11-02	栄研化学株式会社	血清アミロイドａを認識するモノクローナル抗体
EP1416280A3 (en)	1995-09-14	2005-08-10	The Regents of the University of California	Antibodies specific for native PrPsc
US5750361A (en)	1995-11-02	1998-05-12	The Regents Of The University Of California	Formation and use of prion protein (PRP) complexes
CA2235226A1 (en)	1995-11-10	1997-05-15	Elan Corporation, Plc	Peptides which enhance transport across tissues and methods of identifying and using the same
AU1072897A (en)	1995-12-12	1997-07-03	Karolinska Innovations Ab	Peptide binding the klvff-sequence of amyloid beta
JPH09178743A (ja)	1995-12-27	1997-07-11	Oriental Yeast Co Ltd	可溶性ａｐｐの定量法
US6150091A (en)	1996-03-06	2000-11-21	Baylor College Of Medicine	Direct molecular diagnosis of Friedreich ataxia
JP4229341B2 (ja)	1996-03-23	2009-02-25	財団法人阪大微生物病研究会	破傷風毒素の機能的フラグメント抗原及び破傷風ワクチン
CA2183901A1 (en)	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6057367A (en)	1996-08-30	2000-05-02	Duke University	Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en)	1996-11-05	2004-09-28	The Regents Of The University Of California	Somatic cells with ablated PrP gene and methods of use
PT1005368E (pt)	1997-03-10	2009-11-19	Coley Pharm Gmbh	Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
CN1138579C (zh)	1997-03-31	2004-02-18	阿尔萨公司	可扩散植入的释放系统
ATE402717T1 (de) *	1997-04-09	2008-08-15	Intellect Neurosciences Inc	Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
US8173127B2 (en) *	1997-04-09	2012-05-08	Intellect Neurosciences, Inc.	Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US5972269A (en)	1997-06-17	1999-10-26	Taurus International Manufacturing, Inc.	Method of forming cavities in ceramic or metal injection molded parts using a fugitive core
AU8269898A (en)	1997-06-27	1999-01-19	Regents Of The University Of California, The	Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293511B1 (it)	1997-07-30	1999-03-01	Gentili Ist Spa	Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
EP1001987B1 (en)	1997-08-01	2010-12-15	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
US6004925A (en) *	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP2002511385A (ja)	1997-12-03	2002-04-16	ニューララブリミテッド	アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法
NZ504711A (en)	1997-12-03	2002-02-01	Fujisawa Pharmaceutical Co	Soft-pellet drug and process for the preparation thereof
FR2777015B3 (fr)	1998-02-23	2000-09-15	Financ De Biotechnologie	Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
NO314086B1 (no)	1998-05-08	2003-01-27	Gemvax As	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
WO1999060021A2 (en)	1998-05-19	1999-11-25	Yeda Research And Development Co. Ltd.	Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
ATE465178T1 (de)	1998-05-21	2010-05-15	Univ Tennessee Res Foundation	Methoden zur amyloidentfernung mit anti-amyloid- antikörper
US20030147882A1 (en) *	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
AU778270C (en)	1999-01-19	2005-07-21	Pharmacia & Upjohn Company	Gamma-irradiation sterilized polyethylene packaging
CA2361124A1 (en) *	1999-01-22	2000-07-27	Matthew John During	Vaccine-mediated treatment of neurological disorders
PE20010212A1 (es)	1999-06-01	2001-02-22	Neuralab Ltd	Composiciones del peptido a-beta y procesos para producir las mismas
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
AU780474B2 (en)	1999-06-16	2005-03-24	Boston Biomedical Research Institute Incorporated	Immunological control of beta-amyloid levels in vivo
US6294171B2 (en)	1999-09-14	2001-09-25	Milkhaus Laboratory, Inc.	Methods for treating disease states comprising administration of low levels of antibodies
CA2388559A1 (en)	1999-11-29	2001-06-07	Neurochem Inc.	Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ES2275570T3 (es)	1999-12-08	2007-06-16	Intellect Neurosciences, Inc.	Peptidos amiloides beta quimericos.
ATE306933T1 (de)	2000-02-21	2005-11-15	Pharmexa As	Verfahren zur herabregulierung von amyloid
KR100767146B1 (ko)	2000-02-24	2007-10-15	워싱톤 유니버시티	Ａβ 펩티드를 격리시키는 인간화 항체
CA2404237C (en)	2000-04-05	2010-01-26	University Of Tennessee Research Corporation	Methods of investigating, diagnosing, and treating amyloidosis
PT1284998E (pt)	2000-05-22	2005-06-30	Univ New York	Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
EP1309341A2 (en)	2000-07-07	2003-05-14	Lars Lannfelt	Prevention and treatment of alzheimer's disease
EP1172378A1 (en)	2000-07-12	2002-01-16	Richard Dr. Dodel	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20020009445A1 (en)	2000-07-12	2002-01-24	Yansheng Du	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
IT1319277B1 (it)	2000-10-24	2003-09-26	Chiesi Farma Spa	Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en)	2000-10-26	2001-11-25	Marikovsky Moshe	Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
AU2002246734A1 (en)	2000-12-27	2002-08-12	University Of Texas Health Science Center Houston	Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
US20020147882A1 (en) *	2001-04-10	2002-10-10	Pua Khein Seng	Universal serial bus flash memory storage device
DE60121729T2 (de)	2001-04-19	2007-11-29	Dr. Hermann Schätzl	Prion Proteindimere für Impfungen
US20020197258A1 (en)	2001-06-22	2002-12-26	Ghanbari Hossein A.	Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1283030B1 (en) *	2001-08-06	2013-10-02	Kao Corporation	Conditioner composition
EP1545576A2 (en) *	2002-07-30	2005-06-29	Esperion Therapeutics Inc.	Methods of using non-human animal apoliprotein a-i protein
KR101679438B1 (ko) *	2008-09-18	2016-11-24	세다르스-신나이 메디칼 센터	알츠하이머병의 검출을 위한 광학적 방법

2000
- 2000-01-06 UA UA2001118223A patent/UA81216C2/uk unknown
- 2000-06-01 DE DE60045550T patent/DE60045550D1/de not_active Expired - Lifetime
- 2000-06-01 EA EA200101250A patent/EA200101250A1/ru unknown
- 2000-06-01 KR KR1020017015508A patent/KR100930559B1/ko not_active Expired - Lifetime
- 2000-06-01 BR BR0011103-1A patent/BR0011103A/pt not_active Application Discontinuation
- 2000-06-01 WO PCT/US2000/015239 patent/WO2000072876A2/en active Application Filing
- 2000-06-01 PL PL352717A patent/PL202217B1/pl unknown
- 2000-06-01 CA CA2375104A patent/CA2375104C/en not_active Expired - Fee Related
- 2000-06-01 EP EP00938075A patent/EP1185296B1/en not_active Expired - Lifetime
- 2000-06-01 HU HU0201205A patent/HU229986B1/hu unknown
- 2000-06-01 AT AT00938075T patent/ATE495755T1/de active
- 2000-06-01 ES ES10182493.6T patent/ES2445799T3/es not_active Expired - Lifetime
- 2000-06-01 CN CNA2007101032809A patent/CN101091795A/zh active Pending
- 2000-06-01 CZ CZ20014154A patent/CZ302971B6/cs not_active IP Right Cessation
- 2000-06-01 HR HR20010893A patent/HRP20010893A2/hr not_active Application Discontinuation
- 2000-06-01 NZ NZ587223A patent/NZ587223A/en not_active IP Right Cessation
- 2000-06-01 HK HK02106697.1A patent/HK1045117B/en not_active IP Right Cessation
- 2000-06-01 ES ES00938075T patent/ES2362029T3/es not_active Expired - Lifetime
- 2000-06-01 NZ NZ556622A patent/NZ556622A/en not_active IP Right Cessation
- 2000-06-01 KR KR1020097012115A patent/KR20090071673A/ko not_active Withdrawn
- 2000-06-01 MX MXPA01012293A patent/MXPA01012293A/es active IP Right Grant
- 2000-06-01 IL IL14656300A patent/IL146563A0/xx unknown
- 2000-06-01 SG SG200401386-8A patent/SG147275A1/en unknown
- 2000-06-01 TR TR2001/03469T patent/TR200103469T2/xx unknown
- 2000-06-01 EP EP10182493.6A patent/EP2364719B1/en not_active Expired - Lifetime
- 2000-06-01 AU AU53163/00A patent/AU5316300A/en not_active Abandoned
- 2000-06-01 PT PT00938075T patent/PT1185296E/pt unknown
- 2000-06-01 SK SK1718-2001A patent/SK288207B6/sk not_active IP Right Cessation
- 2000-06-01 SG SG200401385-0A patent/SG147274A1/en unknown
- 2000-06-01 KR KR1020107019313A patent/KR101142772B1/ko not_active Expired - Lifetime
- 2000-06-01 CN CN00808358A patent/CN1377278A/zh active Pending
- 2000-06-01 EE EEP200100645A patent/EE05492B1/et unknown
2001
- 2001-11-19 IL IL146563A patent/IL146563A/en not_active IP Right Cessation
- 2001-11-21 IS IS6170A patent/IS2925B/is unknown
- 2001-11-23 BG BG106140A patent/BG65756B1/bg unknown
- 2001-11-23 ZA ZA200109662A patent/ZA200109662B/en unknown
- 2001-11-26 NO NO20015758A patent/NO20015758L/no not_active Application Discontinuation
2007
- 2007-08-20 US US11/842,046 patent/US7977316B2/en not_active Expired - Fee Related
- 2007-08-20 US US11/842,052 patent/US8124081B2/en not_active Expired - Fee Related
2009
- 2009-03-13 US US12/403,414 patent/US20090285822A1/en not_active Abandoned
- 2009-03-30 US US12/414,347 patent/US20090285809A1/en not_active Abandoned
2010
- 2010-07-22 IL IL207166A patent/IL207166A/en not_active IP Right Cessation
- 2010-11-05 US US12/940,750 patent/US20110064734A1/en not_active Abandoned
2011
- 2011-02-23 US US13/033,336 patent/US20110177066A1/en not_active Abandoned
- 2011-02-23 US US13/033,418 patent/US20110182893A1/en not_active Abandoned
- 2011-04-18 US US13/088,983 patent/US20110287049A1/en not_active Abandoned
- 2011-04-19 CY CY20111100403T patent/CY1111639T1/el unknown

Also Published As

Publication number	Publication date
CZ20014154A3 (cs)	2002-11-13
SG147274A1 (en)	2008-11-28
ATE495755T1 (de)	2011-02-15
HK1045117A1 (en)	2002-11-15
US8124081B2 (en)	2012-02-28
IS2925B (is)	2015-06-15
IL146563A0 (en)	2002-07-25
US20110182893A1 (en)	2011-07-28
CN101091795A (zh)	2007-12-26
EA200101250A1 (ru)	2002-06-27
ES2445799T3 (es)	2014-03-05
KR20100099355A (ko)	2010-09-10
BG106140A (bg)	2002-08-30
WO2000072876A2 (en)	2000-12-07
KR100930559B1 (ko)	2009-12-09
CZ302971B6 (cs)	2012-01-25
KR20020025884A (ko)	2002-04-04
BR0011103A (pt)	2002-03-19
IL146563A (en)	2010-11-30
PT1185296E (pt)	2011-04-19
EP1185296A2 (en)	2002-03-13
US20110287049A1 (en)	2011-11-24
SG147275A1 (en)	2008-11-28
PL202217B1 (pl)	2009-06-30
NO20015758L (no)	2002-01-30
EP2364719B1 (en)	2013-11-13
HU229986B1 (en)	2015-04-28
CN1377278A (zh)	2002-10-30
NO20015758D0 (no)	2001-11-26
KR101142772B1 (ko)	2012-05-18
BG65756B1 (bg)	2009-10-30
US20080248029A1 (en)	2008-10-09
HRP20010893A2 (en)	2003-04-30
IL207166A (en)	2013-11-28
NZ556622A (en)	2009-03-31
ZA200109662B (en)	2003-05-23
IS6170A (is)	2001-11-21
SK288207B6 (sk)	2014-07-02
CA2375104C (en)	2013-12-24
TR200103469T2 (tr)	2002-05-21
US20110177066A1 (en)	2011-07-21
KR20090071673A (ko)	2009-07-01
HK1045117B (en)	2011-08-05
MXPA01012293A (es)	2002-11-07
HUP0201205A2 (en)	2002-08-28
IL207166A0 (en)	2010-12-30
EP2364719A1 (en)	2011-09-14
PL352717A1 (en)	2003-09-08
US7977316B2 (en)	2011-07-12
EE05492B1 (et)	2011-12-15
US20090285809A1 (en)	2009-11-19
DE60045550D1 (de)	2011-03-03
SK17182001A3 (sk)	2002-09-10
AU5316300A (en)	2000-12-18
CY1111639T1 (el)	2015-10-07
HUP0201205A3 (en)	2004-07-28
ES2362029T3 (es)	2011-06-27
EP1185296B1 (en)	2011-01-19
US20090285822A1 (en)	2009-11-19
HK1160392A1 (en)	2012-08-17
US20080248023A1 (en)	2008-10-09
UA81216C2 (en)	2007-12-25
WO2000072876A3 (en)	2001-05-03
NZ587223A (en)	2011-12-22
CA2375104A1 (en)	2000-12-07
US20110064734A1 (en)	2011-03-17

Publication	Publication Date	Title
EE200100645A (et)	2003-02-17	Amüloidogeense haiguse preventsioon ja ravi
CY1105922T1 (el)	2011-04-06	Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
TW264480B (et)	1995-12-01
ATE153534T1 (de)	1997-06-15	Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
CY1108331T1 (el)	2014-02-12	Προληψη και θεραπεια αμυλοειδογονου νοσου
NO20022531D0 (no)	2002-05-28	Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
DE69831971D1 (de)	2006-03-02	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE602004021797D1 (de)	2009-08-13	Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
DK1137410T3 (da)	2006-12-27	Hidtil ukendte 4-dedimethylaminotetracyclinderivater
DE60221665D1 (de)	2007-09-20	Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
EP1040830A4 (en)	2002-10-23	REMEDY FOR NEURODEGENERATIVE DISEASES
DE69526216D1 (de)	2002-05-08	Antifungaleverfahren und mitteln
NO20000771D0 (no)	2000-02-16	Anvendelse av fankinon for behandling av Alzheimers sykdom
DK0821969T3 (da)	2007-03-26	Medicinsk sammensætning omfattende TCF-II
FI961494L (fi)	1996-04-03	Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
DE60004093D1 (de)	2003-08-28	Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
DK8893D0 (da)	1993-01-26	Medicament for treatment or prevention of disease

Legal Events

Date	Code	Title	Description
2008-08-15	GB1A	Change in the ownership or in the address of the owner
2013-06-17	GB1A	Change in the ownership or in the address of the owner